Skip to main content

Table 4 Description of patients at the day of VAP diagnosis

From: Relationship between corticosteroid use and incidence of ventilator-associated pneumonia in COVID-19 patients: a retrospective multicenter study

 

No corticosteroids (n = 138)

Corticosteroids (n = 74)

Total number of VAP

 1

103/138 (74.6)

66/74 (89.2)

 2

29/138 (21.0)

6/74 (8.1)

 3

5/138 (3.6)

1/74 (1.4)

 4

1/138 (0.7)

1/74 (1.4)

 5

0/138 (0.0)

1/74 (1.4)

SOFA scorea

8 (5–11)

8 (5–11)

Diagnostic procedure

 Endotracheal aspirates

83/137 (60.6)

47/73 (64.4)

 Bronchoalveolar lavage

54/137 (39.4)

26/73 (35.6)

Modified CPISa

6 (5–7)

6 (4–7)

PaO2/FiO2b

130 (91–180)

139 (95–188)

Antibiotic treatment

122/138 (88.4)

71/74 (95.9)

Appropriate antibiotic treatment

94/133 (70.7)

48/73 (65.8)

  1. Values are as no./No.(%) or median (interquartile range)
  2. VAP ventilator-associated pneumonia, SOFA Sequential Organ Failure Assessment, CPIS clinical pulmonary infection score
  3. a8 missing values (1 in corticosteroids group)
  4. b13 missing values (3 in corticosteroids group)